tbuckley/cabot-search huggingface dataset:
Lifetime Cost-Effectiveness of Structured Education and Exercise Therapy for Knee Osteoarthritis in Australia
Authors: Sean Docking, Zanfina Ademi, Christian Barton, Jason A. Wallis, Ian A. Harris, Richard de Steiger, Rachelle Buchbinder, Natasha Brusco, Kirby Young, Marcella Ferraz Pazzinatto, Dylan Harries, Christopher J. Vertullo, Ilana N. Ackerman
Journal: JAMA Network Open (2024)

Importance Structured education and exercise therapy programs have been proposed to reduce reliance on total knee replacement (TKR) surgery and improve health care sustainability. The long-term cost-effectiveness of these programs is unclear. Objectives To estimate the lifetime cost-effectiveness of implementing a national structured education and exercise therapy program for individuals with knee osteoarthritis with the option for future TKR compared with usual care (TKR for all). Design, Setting, and Participants This economic evaluation used a life table model in combination with a Markov model to compare costs and health outcomes of a national education and exercise therapy program vs usual care in the Australian health care system. Subgroup, deterministic, and probabilistic sensitivity analyses were completed. A hypothetical cohort of adults aged 45 to 84 years who would undergo TKR was created. Exposure Structured education and exercise therapy intervention provided by physiotherapists. The comparator was usual care where all people undergo TKR without accessing the program in the first year. Main Outcomes and Measures Incremental net monetary benefit (INMB), with an incremental cost-effectiveness ratio threshold of 28 033 Australian dollars (A$) per quality-adjusted life-year (QALY) gained, was calculated from a health care perspective. Transition probabilities, costs, and utilities were estimated from national registries and a randomized clinical trial. Results The hypothetical cohort included 61 394 individuals (53.9% female; 93.6% aged ≥55 years). Implementation of an education and exercise therapy program resulted in a lifetime cost savings of A$498 307 942 (US $339 922 227), or A$7970 (US $5537) per individual, and resulted in fewer QALYs (0.43 per individual) compared with usual care. At a population level, education and exercise therapy was not cost-effective at the lifetime horizon (INMB, −A$4090 [−US $2841]). Subgroup analysis revealed that the intervention was cost-effective only for the first 9 years and over a lifetime only in individuals with no or mild pain at baseline (INMB, A$11 [US $8]). Results were robust to uncertainty around model inputs. Conclusions and Relevance In this economic evaluation of structured education and exercise therapy compared with usual care, the intervention was not cost-effective over the lifetime for all patients but was for the first 9 years and for those with minimal pain. These findings point to opportunities to invest early cost savings in additional care or prevention, including targeted implementation to specific subgroups.
Hearing Loss, Hearing Aids, and Cognition
Authors: Baptiste Grenier, Claudine Berr, Marcel Goldberg, Xavier Jouven, Marie Zins, Jean-Philippe Empana, Quentin Lisan
Journal: JAMA Network Open (2024)

Most observational studies examining the association between hearing loss (HL) and cognitive impairment used subjective measures of hearing and addressed only one dimension of cognition, and very few investigated the potential benefit of hearing aids (HAs).
Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome
Authors: Ana Barettino, Cristina González-Gómez, Pilar Gonzalo, María J Andrés-Manzano, Carlos R Guerrero, Francisco M Espinosa, Rosa M Carmona, Yaazan Blanco, Beatriz Dorado, Carlos Torroja, Fátima Sánchez-Cabo, Ana Quintas, Alberto Benguría, Ana Dopazo, Ricardo García, Ignacio Benedicto, Vicente Andrés
Journal: Journal of Clinical Investigation (2024)

Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare disease caused by the expression of progerin, an aberrant protein produced by a point mutation in the LMNA gene. HGPS patients show accelerated aging and die prematurely mainly from complications of atherosclerosis such as myocardial infarction, heart failure, or stroke. However, the mechanisms underlying HGPS vascular pathology remain ill defined. We used single-cell RNA sequencing to characterize the aorta in progerin-expressing LmnaG609G/G609G mice and wild-type controls, with a special focus on endothelial cells (ECs). HGPS ECs showed gene expression changes associated with extracellular matrix alterations, increased leukocyte extravasation, and activation of the yes-associated protein 1/transcriptional activator with PDZ-binding domain (YAP/TAZ) mechanosensing pathway, all validated by different techniques. Atomic force microscopy experiments demonstrated stiffer subendothelial extracellular matrix in progeroid aortas, and ultrasound assessment of live HGPS mice revealed disturbed aortic blood flow, both key inducers of the YAP/TAZ pathway in ECs. YAP/TAZ inhibition with verteporfin reduced leukocyte accumulation in the aortic intimal layer and decreased atherosclerosis burden in progeroid mice. Our findings identify endothelial YAP/TAZ signaling as a key mechanism of HGPS vascular disease and open a new avenue for the development of YAP/TAZ targeting drugs to ameliorate progerin-induced atherosclerosis.
Neuropilin-2 expressing cells in breast cancer are S-nitrosylation hubs that mitigate radiation-induced oxidative stress
Authors: Ayush Kumar, Hira Goel, Christi Wisniewski, Tao Wang, Yansong Geng, Mengdie Wang, Shivam Goel, Kai Hu, Rui Li, Lihua J Zhu, Jennifer L Clark, Lindsay M Ferreira, Michael Brehm, Thomas J Fitzgerald, Arthur M Mercurio
Journal: Journal of Clinical Investigation (2024)

The high rate of recurrence after radiation therapy in triple-negative breast cancer (TNBC) indicates that novel approaches and targets are needed to enhance radiosensitivity. Here, we report that neuropilin-2 (NRP2), a receptor for vascular endothelial growth factor (VEGF) that is enriched on sub-populations of TNBC cells with stem cell properties, is an effective therapeutic target for sensitizing TNBC to radiotherapy. Specifically, VEGF/NRP2 signaling induces nitric oxide synthase 2 (NOS2) transcription by a mechanism dependent on Gli1. NRP2-expressing tumor cells serve as a hub to produce nitric oxide (NO), an autocrine and paracrine signaling metabolite, which promotes cysteine-nitrosylation of Kelch-like ECH-asssociated protein 1 (KEAP1) and, consequently, nuclear factor erythroid 2-related factor 2 (NFE2L2)-mediated transcription of antioxidant response genes. Inhibiting VEGF binding to NRP2, using a humanized monoclonal antibody (mAb), results in NFE2L2 degradation via KEAP1 rendering cell lines and organoids vulnerable to irradiation. Importantly, treatment of patient-derived xenografts with the NRP2 mAb and radiation resulted in significant tumor necrosis and regression compared to radiation alone. Together, these findings reveal a targetable mechanism of radioresistance and they support the use of NRP2 mAb as an effective radiosensitizer in TNBC.
The epigenetic state of the cell of origin defines mechanisms of leukemogenesis
Authors: Zhiheng Li, Sara Fierstein, Mayuri Tanaka-Yano, Katie Frenis, Chun-Chin Chen, Dahai Wang, Marcelo Falchetti, Parker Côté, Christina Curran, Kate Lu, Tianxin Liu, Stuart Orkin, Hojun Li, Edroaldo Lummertz da Rocha, Shaoyan Hu, Qian Zhu, R Grant Rowe
Journal: Leukemia (2024)
Melanoma as a detection-dependent cancer: proxy measures of screening and surveillance associated with 3-year incidence of detection procedures for skin cancer in a national prospective study
Authors: Nirmala Pandeya, Catherine M Olsen, Rachel E Neale, David C Whiteman
Journal: British Journal of Dermatology (2024)

Abstract Background Increased levels of skin detection activities are suspected of driving recent rapid increases in melanoma incidence. While ecological studies report rising rates of skin biopsies in many industrialised populations, few studies have accessed individual-level clinical data to test the hypothesis that people exposed to skin screening and surveillance go on to experience higher levels of biopsies and excisions, and higher incidence of melanoma. Objective To measure the incidence rates of detection events and melanoma diagnoses in a national cohort during follow-up, stratified according to screening or surveillance activities in the index year. Methods We conducted a prospective cohort study of 10,674,200 men and women using linked data from Australia’s universal health insurance scheme (2011-2016). Participants who underwent biopsies or who were diagnosed in skin cancer in 2011/2012 were excluded. We then defined participants as surveilled, screened, or unscreened for skin cancer based on medical claims occurring in 2013. We compared rates of biopsies, excisions for suspected melanoma, and excisions for histologically confirmed melanoma during follow-up (2014-2016). Results After adjusting for socio-demographic factors, screened people were significantly more likely than unscreened people to undergo skin biopsies (RR 2.59, 95% CI 2.56-2.63), excisions for suspected melanoma (RR 2.57, 95%CI 2.53-2.60), and excisions for confirmed melanoma (hazard ratio 3.32, 95% CI 3.24-3.40) during follow-up. Similarly elevated rates of subsequent diagnostic events were observed for the surveilled group. Importantly, rates of detection and rates of melanoma remained elevated in each of the subsequent years of follow-up among those who were screened or surveilled in the index year. Conclusions People undergoing skin screening or surveillance subsequently experience higher rates of diagnostic scrutiny and higher rates of melanoma.
Synergistic activity of <i>Enterococcus Faeciu</i> m-induced ferroptosis via expansion of IFN-γ <sup>+</sup> CD8 <sup>+</sup> T cell population in advanced hepatocellular carcinoma treated with sorafenib
Authors: Haitao Yu, Ganglian Lin, Junyan Jiang, Jiangqiao Yao, Zhenyan Pan, Haonan Xie, Zhiyuan Bo, Qikuan He, Jinhuan Yang, Ziyan Chen, Jiacheng Li, Yi Wang, Zhengping Yu, Yehuda G. Assaraf, Gang Chen
Journal: Gut Microbes (2024)

The gut microbiota plays an important role in the development and treatment of hepatocellular carcinoma (HCC). However, the implication of specific gut microbiota in targeted sorafenib therapy for advanced HCC and the microbiota mode of action, remain to be elucidated. Here, we confirmed that four bacterial genera,
The role of microbial indole metabolites in tumor
Authors: Dingjiacheng Jia, Zheng Kuang, Liangjing Wang
Journal: Gut Microbes (2024)

The gut microbiota can produce a variety of microbial-derived metabolites to influence tumor development. Tryptophan, an essential amino acid in the human body, can be converted by microorganisms via the indole pathway to indole metabolites such as Indole-3-Lactic Acid (ILA), Indole-3-Propionic Acid (IPA), Indole Acetic Acid (IAA) and Indole-3-Aldehyde (IAld). Recent studies have shown that indole metabolites play key roles in tumor progression, and they can be used as adjuvant regimens for tumor immunotherapy or chemotherapy. Here, we summarize recent findings on the common microbial indole metabolites and provide a review of the mechanisms of different indole metabolites in the tumor microenvironment. We further discuss the limitations of current indole metabolite research and future possibilities. It is expected that microbial indole metabolites will provide new strategies for clinical therapy.
Paclitaxel chemotherapy disrupts microbiota-enterohepatic bile acid metabolism in mice
Authors: Brett R. Loman, Zainab Alzoubi, Alexis J. Lynch, Robert M. Jaggers, Kelley Jordan, Corena V. Grant, Lynette K. Rogers, Leah M. Pyter, Michael T. Bailey
Journal: Gut Microbes (2024)

Balanced interactions between the enteric microbiota and enterohepatic organs are essential to bile acid homeostasis, and thus normal gastrointestinal function. Disruption of these interactions by cancer treatment instigates bile acid malabsorption, leading to treatment delays, malnutrition, and decreased quality of life. However, the nature of chemotherapy-induced bile acid malabsorption remains poorly characterized with limited treatment options. Therefore, this study sought to characterize changes in hepatic, enteric, and microbial bile acid metabolism in a mouse model of chemotherapy-induced toxicity. Consistent with clinical bile acid malabsorption, chemotherapy increased fecal excretion of primary bile acids and water, while diminishing microbiome diversity, secondary bile acid formation, and small intestinal bile acid signaling. We identified new contributors to pathology of bile acid malabsorption in the forms of lipopolysaccharide-induced cholestasis and colonic crypt hyperplasia from reduced secondary bile acid signaling. Chemotherapy reduced markers of hepatic bile flow and bile acid synthesis, elevated markers of fibrosis and endotoxemia, and altered transcription of genes at all stages of bile acid metabolism. Primary hepatocytes exposed to lipopolysaccharide (but not chemotherapy) replicated chemotherapy-induced transcriptional differences, while gut microbial transplant into germ-free mice replicated very few differences. In the colon, chemotherapy-altered bile acid profiles (particularly higher tauromuricholic acid and lower hyodeoxycholic acid) coincided with crypt hyperplasia. Exposing primary colonoids to hyodeoxycholic acid reduced proliferation, while gut microbiota transplant enhanced proliferation. Together, these investigations reveal complex involvement of the entire microbiota-enterohepatic axis in chemotherapy-induced bile acid malabsorption. Interventions to reduce hepatic lipopolysaccharide exposure and enhance microbial bile acid metabolism represent promising co-therapies to cancer treatment.
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ
Authors: Thomas Zeyen, Laura Böhm, Daniel Paech, Niklas Schäfer, Theophilos Tzaridis, Cathrina Duffy, Louisa Nitsch, Matthias Schneider, Anna-Laura Potthoff, Javen Lennard Schneider-Rothhaar, Joachim Peter Steinbach, Peter Hau, Thomas Kowalski, Clemens Seidel, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Pia Susan Zeiner, Ghazaleh Tabatabai, Norbert Galldiks, Walter Stummer, Elke Hattingen, Martin Glas, Eleni Gkika, Hartmut Vatter, Alexander Radbruch, Ulrich Herrlinger, Johannes Weller, Christina Schaub
Journal: Neuro-Oncology (2024)

Abstract Background Maximum tumor resection improves overall survival (OS) in patients with glioblastoma. The extent of resection (EOR) is historically dichotomized. The response assessment in neuro-oncology (RANO) resects group recently proposed criteria for volumetry-based EOR assessment in patients that were treated according to Stupp´s protocol. The purpose of this study was (1) to investigate the prognostic value of EOR in patients receiving combined chemotherapy with lomustine (CCNU)/temozolomide (TMZ), and (2) to analyze the prognostic performance of binary EOR assessment compared to volumetric assessment. Methods Seventy-eight patients with newly diagnosed MGMT-methylated GBM undergoing tumor resection followed by radiochemotherapy with CCNU/TMZ were included in this study. Residual contrast-enhancing (CE) tumor volume after the first resection was measured and its influence on OS and progression-free survival was analyzed using uni- and multivariable Cox regression analysis as well as two-sided log-rank test. Patients were divided into residual tumor volume (RTV) ≤1 cm³, &amp;gt;1–≤5 cm³, and &amp;gt;5 cm³ following the proposed criteria of the RANO resect group. Results Prolonged OS was associated with age &amp;lt;60 years, low RTV, and gross total resection. RTV had a superior prognostic value compared to binary EOR assessment. Patients with total or near total resection of CE tumor (≤ 1 cm³ RTV) showed prolonged OS (median 54.4 months, 95% CI: 46.94–not reached), with a 5-year survival rate of 49%. Conclusions Low RTV is associated with increased survival in glioblastoma patients undergoing radiochemotherapy with CCNU/TMZ. This study demonstrates the applicability of the recently proposed RANO resect criteria in this subgroup of patients.
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
Authors: Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos, Stephane DeBotton, Roland B Walter, Kristen Pettit, Michael R Savona, Mithun Vinod Shah, Marina Kremyanskaya, Maria R Baer, James M Foran, Gary Schiller, Lionel Adès, Mael Heiblig, Celine Berthon, Pierre Peterlin, Eduardo Rodríguez-Arbolí, Olga Salamero, Mrinal M Patnaik, Cristina Papayannidis, Jolanta Grembecka, Tomasz Cierpicki, Bradley Clegg, Joshua Ray, Brian M Linhares, Kun Nie, Amitava Mitra, Julie Mackey Ahsan, Marilyn Tabachri, Harris S Soifer, Daniel Corum, Mollie Leoni, Stephen Dale, Amir T Fathi
Journal: The Lancet Oncology (2024)
Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study
Authors: Sudha Sundar, Ridhi Agarwal, Clare Davenport, Katie Scandrett, Susanne Johnson, Partha Sengupta, Radhika Selvi-Vikram, Fong Lien Kwong, Sue Mallett, Caroline Rick, Sean Kehoe, Dirk Timmerman, Tom Bourne, Ben Van Calster, Hilary Stobart, Richard D Neal, Usha Menon, Alex Gentry-Maharaj, Lauren Sturdy, Ryan Ottridge, Jon Deeks
Journal: The Lancet Oncology (2024)
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Authors: Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, Noemi Reguart, Pierre-Jean Souquet, Egbert F Smit, Sergey V Orlov, Johan Vansteenkiste, Makoto Nishio, Maja de Jonge, Wallace Akerley, Edward B Garon, Harry J M Groen, Daniel S W Tan, Takashi Seto, Garrett M Frampton, Anna Robeva, Mariana Carbini, Sylvie Le Mouhaer, Alejandro Yovine, Aislyn Boran, Claudia Bossen, Yiqun Yang, Lexiang Ji, Lauren Fairchild, Rebecca S Heist
Journal: The Lancet Oncology (2024)
A brave new framework for glioma drug development
Authors: Kelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, Marjolein Geurts, Timothy F Cloughesy, Jason Huse, Elizabeth S Duke, Justin Lathia, David M Ashley, Edjah K Nduom, Georgina Long, Kirit Singh, Anthony Chalmers, Manmeet S Ahluwalia, Amy Heimberger, Stephen Bagley, Tomoki Todo, Roel Verhaak, Patrick D Kelly, Shawn Hervey-Jumper, John de Groot, Anoop Patel, Peter Fecci, Ian Parney, Victoria Wykes, Colin Watts, Terry C Burns, Nader Sanai, Matthias Preusser, Joerg Christian Tonn, Katharine J Drummond, Michael Platten, Sunit Das, Kirk Tanner, Michael A Vogelbaum, Michael Weller, James R Whittle, Mitchel S Berger, Mustafa Khasraw
Journal: The Lancet Oncology (2024)
Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO)
Authors: Zachary S Zumsteg, Siddharth Sheth, Salma K Jabbour, Krishnan R Patel, Randall J Kimple, Terence M Williams, Meng Xu-Welliver, Pedro A Torres-Saavedra, Arta M Monjazeb, Jyoti Mayadev, Steven E Finkelstein, John M Buatti, Sandip P Patel, Steven H Lin
Journal: The Lancet Oncology (2024)
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies
Authors: Foram Khatsuria, Christel McMullan, Olalekan Lee Aiyegbusi, Karen L Shaw, Roshina Iqbal, Francesca Kinsella, Keith Wilson, Lester Pyatt, Marlene Lewis, Sophie M R Wheldon, David Burns, Ronjon Chakraverty, Melanie Calvert, Sarah E Hughes
Journal: The Lancet Oncology (2024)
Global Progression Rates of Precursor Lesions for Gastric Cancer: A Systematic Review and Meta-Analysis
Authors: Anne I Hahn, Duco T Mülder, Robert J Huang, Margaret J Zhou, Benjamin Blake, Omonefe Omofuma, John D Murphy, Daniela S Gutiérrez-Torres, Ann G Zauber, James F O'Mahony, M Constanza Camargo, Uri Ladabaum, Jennifer M Yeh, Chin Hur, Iris Lansdorp-Vogelaar, Reinier Meester, Monika Laszkowska
Journal: Clinical Gastroenterology and Hepatology (2024)
Plasma exchange does not improve overall survival in patients with acute liver failure in a real world cohort
Authors: Laura Burke, William Bernal, Tasneem Pirani, Banwari Agarwal, Rajiv Jalan, Jennifer Ryan, Mansoor Nawaz Bangash, Phillip El-Dalil, Nick Murphy, Mhairi Donnelly, Janice Davidson, Ken Simpson, Hannah Giles, Phyo Set Mone, Steven Masson, Andrew Davenport, Ian Rowe, Joanna Moore
Journal: Journal of Hepatology (2024)
Fam3a-mediated prohormone convertase switch in α-cells regulates pancreatic GLP-1 production in an Nr4a2-Foxa2-dependent manner
Authors: Dandan Wang, Tianjiao Wei, Xiaona Cui, Li Xia, Yafei Jiang, Deshan Yin, Xinyue Liao, Fei Li, Jian Li, Qi Wu, Xiafang Lin, Shan Lang, Yunyi Le, Jichun Yang, Jin Yang, Rui Wei, Tianpei Hong
Journal: Metabolism (2024)
Machine learning explains response variability of deep brain stimulation on Parkinson’s disease quality of life
Authors: Enrico Ferrea, Farzin Negahbani, Idil Cebi, Daniel Weiss, Alireza Gharabaghi
Journal: npj Digital Medicine (2024)

Abstract Improving health-related quality of life (QoL) is crucial for managing Parkinson’s disease. However, QoL outcomes after deep brain stimulation (DBS) of the subthalamic nucleus (STN) vary considerably. Current approaches lack integration of demographic, patient-reported, neuroimaging, and neurophysiological data to understand this variability. This study used explainable machine learning to analyze multimodal factors affecting QoL changes, measured by the Parkinson’s Disease Questionnaire (PDQ-39) in 63 patients, and quantified each variable’s contribution. Results showed that preoperative PDQ-39 scores and upper beta band activity (&gt;20 Hz) in the left STN were key predictors of QoL changes. Lower initial QoL burden predicted worsening, while improvement was associated with higher beta activity. Additionally, electrode positions along the superior-inferior axis, especially relative to the z = −7 coordinate in standard space, influenced outcomes, with improved and worsened QoL above and below this marker. This study emphasizes a tailored, data-informed approach to optimize DBS treatment and improve patient QoL.
Estimates of the burden of human rabies deaths and animal bites in India, 2022–23: a community-based cross-sectional survey and probability decision-tree modelling study
Authors: Jeromie Wesley Vivian Thangaraj, Navaneeth S Krishna, Shanmugasundaram Devika, Suganya Egambaram, Sudha Rani Dhanapal, Siraj Ahmed Khan, Ashok Kumar Srivastava, Ayush Mishra, Basavaraj Shrinivasa, Devendra Gour, Major Madhukar, Nirmal Verma, Parul Sharma, Ravinder Kumar Soni, Sabarinathan Ramasamy, Sreelakshmi Mohandas, Subrata Baidya, Tanveer Rehman, Vijay V Yeldandi, Akashdeep Singh, Aswathy Sreedevi, Babasaheb V Tandale, Debjani Ram Purakayastha, Mahendra M Reddy, Manju Toppo, Nitinkumar Valjibhai Solanki, Pramit Ghosh, Prashant Jaiswal, Shaili Vyas, Shampa Das, Subrata Kumar Palo, Venela Prasanth, Amanda G A Rozario, Chokkalingam Durairajan, Anitha Delli, Aruna Sasi, Chandhini Pandiyan, Doddabale Hanumanthaiah Ashwathnarayana, Sam Joy, Srikrishna Isloor, Mysore Kalappa Sudarshan, Manju Rahi, Manoj V Murhekar
Journal: The Lancet Infectious Diseases (2024)
Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups
Authors: Omran Saifi, Chelsea C Pinnix, Leslie K Ballas, Chris R Kelsey, Sarah A Milgrom, Stephanie A Terezakis, Nicholas B Figura, Rahul R Parikh, John C Grecula, Stella Flampouri, Chul S Ha, Andrea C Lo, John P Plastaras, David C Hodgson, Bradford S Hoppe
Journal: The Lancet Haematology (2024)